Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis...

Source: BMC Pulmonary Medicine - March 3, 2016 Category: Respiratory Medicine Authors: Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Hideaki Yamakawa, Masato Morita, Hideya Kitamura and Takashi Ogura Source Type: research